Literature DB >> 19122741

Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego).

Angela Dispenzieri1, Giampaolo Merlini, Raymond L Comenzo.   

Abstract

Entities:  

Year:  2008        PMID： 19122741      PMCID： PMC2330327          DOI： 10.1016/j.bbmt.2007.10.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  47 in total

1.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

2.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

3.  Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.

Authors:  David C Seldin; Elie B Choufani; Laura M Dember; Janice F Wiesman; John L Berk; Rodney H Falk; Carl O'Hara; Salli Fennessey; Kathleen T Finn; Daniel G Wright; Martha Skinner; Vaishali Sanchorawala
Journal:  Clin Lymphoma       Date:  2003-03

4.  Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis.

Authors:  Giovanni Palladini; Robert A Kyle; Dirk R Larson; Terry M Therneau; Giampaolo Merlini; Morie A Gertz
Journal:  Amyloid       Date:  2005-06       Impact factor: 7.141

5.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

6.  Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.

Authors:  A Dispenzieri; M Q Lacy; R A Kyle; T M Therneau; D R Larson; S V Rajkumar; R Fonseca; P R Greipp; T E Witzig; J A Lust; M A Gertz
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

7.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

8.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Authors:  R A Kyle; M A Gertz; P R Greipp; T E Witzig; J A Lust; M Q Lacy; T M Therneau
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 9.  Primary systemic amyloidosis--a diagnostic primer.

Authors:  M A Gertz; R A Kyle
Journal:  Mayo Clin Proc       Date:  1989-12       Impact factor: 7.616

10.  Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

Authors:  Giovanni Palladini; Vittorio Perfetti; Laura Obici; Riccardo Caccialanza; Alessandra Semino; Fausto Adami; Giobatta Cavallero; Roberto Rustichelli; Giovambattista Virga; Giampaolo Merlini
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113
View more
  4 in total

1.  Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.

Authors:  Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; Tow Tan; Shirshendu Sinha; Nelson Leung; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Am J Hematol       Date:  2011-02-15       Impact factor: 10.047

2.  Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.

Authors:  Shawn C Pun; Heather J Landau; Elyn R Riedel; Jonathan Jordan; Anthony F Yu; Hani Hassoun; Carol L Chen; Richard M Steingart; Jennifer E Liu
Journal:  J Am Soc Echocardiogr       Date:  2017-10-27       Impact factor: 5.251

3.  Prevalence and determinants of iron deficiency in cardiac amyloidosis.

Authors:  Antoine Jobbé-Duval; Mélanie Bézard; Stéphane Moutereau; Mounira Kharoubi; Silvia Oghina; Amira Zaroui; Arnault Galat; Coraline Chalard; Elisabeth Hugon-Vallet; Francois Lemonnier; Damien Eyharts; Elsa Poulot; Pascale Fanen; Benoit Funalot; Valérie Molinier-Frenkel; Vincent Audard; Luc Hittinger; Marc Antoine Delbarre; Emmanuel Teiger; Thibaud Damy
Journal:  ESC Heart Fail       Date:  2022-02-06

4.  Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.

Authors:  H Landau; M Smith; C Landry; J F Chou; S M Devlin; H Hassoun; C Bello; S Giralt; R L Comenzo
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.